Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$4.39M, compared with $8.56M a year earlier. Trailing-twelve-month other income / expenses was -$9.98M.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$4.39M or moves back toward the trailing-twelve-month quarterly average of -$2.5M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 2.96M USD
- Year-over-year change
- +164.2%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.96M | +164.2% |
| FY2024 | 2024-12-31 | (4.61M) | +52.8% |
| FY2023 | 2023-12-31 | (9.77M) | -162733.3% |
| FY2022 | 2022-12-31 | (6K) | +99.4% |
| FY2021 | 2021-12-31 | (1.04M) | — |
Other Income / Expenses vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -163.6% is the 9th highest of 10, against a peer median of -3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.62M USD | +427.9% | +121.1% | — | |
| LTM Mar 2026 | $5.35M USD | +16.3% | — | — | |
| LTM Mar 2026 | $5.34M USD | -44.5% | +19.2% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.09M USD | -46.1% | +60.9% | — |
| LTM Mar 2026 | $1.47M USD | -57.0% | -25.8% | — | |
| LTM Mar 2026 | -$675K USD | -3.2% | — | 0.3% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | -CA$1.17M CAD | +96.8% | — | 6.4% |
| LTM Mar 2026 | -$9.98M USD | -163.6% | — | — | |
| LTM Mar 2026 | -$34.27M USD | -2325.3% | — | 871.1% | |
CBUSCibus, Inc. | LTM Mar 2026 | -$45.03M USD | -1.1% | — | 1050.7% |
| Peer median (excluding UNCY) | — | -3.2% | +40.1% | 438.7% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 951K | 675K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 572K |
| Gross Profit | 0 | 951K | 675K | 0 | (572K) |
| Gross Margin | — | 100.0% | 100.0% | — | — |
| Research & Development | 6.08M | 12.44M | 12.9M | 20.01M | 9.12M |
| Selling, General & Admin | 2.9M | 6.57M | 8.55M | 12.1M | 20.4M |
| Operating Expenses | 8.98M | 19M | 21.45M | 32.12M | 28.95M |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| EBITDA | (9.38M) | (17.89M) | (30.18M) | (36.23M) | (25.91M) |
| EBITDA Margin | — | -1881.3% | -4470.8% | — | — |
| Operating Income | (8.98M) | (18.05M) | (20.77M) | (32.12M) | (29.52M) |
| Operating Margin | — | -1898.2% | -3077.6% | — | — |
| Interest Income | 0 | 0 | 615K | 1.26M | 1.01M |
| Interest Expense | 628K | 6K | 82K | 71K | 71K |
| Other Income / Expenses | (1.04M) | (6K) | (9.77M) | (4.61M) | 2.96M |
| Income Before Tax | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Pre-Tax Margin | — | -1898.8% | -4525.0% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Net Margin | — | -1898.8% | -4525.0% | — | — |
| EPS (Basic) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| EPS (Diluted) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| Weighted Avg Shares | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
| Weighted Avg Shares (Diluted) | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.